Mail

UK markets closed

FTSE 100
8,213.49
+41.34(+0.51%)
FTSE 250
20,164.54
+112.21(+0.56%)
AIM
771.53
+3.42(+0.45%)
GBP/EUR
1.1653
-0.0030(-0.25%)
GBP/USD
1.2549
+0.0016(+0.13%)
Bitcoin GBP
49,290.19
+2,049.32(+4.34%)

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

GC Biopharma Corp. (006280.KS)

KSE - KSE Delayed price. Currency in KRW

Add to watchlist

113,500.00

-2,200.00

(-1.90%)

At close: 03:30PM KST

Currency in KRW

Valuation measures⁴

Market cap (intra-day)	1.32T
Enterprise value	1.99T
Trailing P/E	21.15
Forward P/E	17.54
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	0.81
Price/book (mrq)	1.02
Enterprise value/revenue	1.22
Enterprise value/EBITDA	25.75

Trading information

Stock price history

Beta (5Y monthly)	1.09
52-week change ³	-8.47%
S&P500 52-week change ³	22.43%
52-week high ³	134,300.00
52-week low ³	93,000.00
50-day moving average ³	117,744.00
200-day moving average ³	114,018.50

Share statistics

Avg vol (3-month) ³	20.17k
Avg vol (10-day) ³	12k
Shares outstanding ⁵	11.41M
Implied shares outstanding ⁶	11.45M
Float ⁸	5.45M
% held by insiders ¹	51.45%
% held by institutions ¹	12.77%
Shares short ⁴	N/A
Short ratio ⁴	N/A
Short % of float ⁴	N/A
Short % of shares outstanding ⁴	N/A
Shares short (prior month ) ⁴	N/A

Dividends & splits

Forward annual dividend rate ⁴	1500
Forward annual dividend yield ⁴	1.30%
Trailing annual dividend rate ³	N/A
Trailing annual dividend yield ³	N/A
5-year average dividend yield ⁴	0.96
Payout ratio ⁴	1,080.25%
Dividend date ³	N/A
Ex-dividend date ⁴	27 Dec 2023
Last split factor ²	1.05:1
Last split date ³	07 Jun 2013

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	-1.64%
Operating margin (ttm)	-2.21%

Management effectiveness

Return on assets (ttm)	0.82%
Return on equity (ttm)	-1.27%

Income statement

Revenue (ttm)	1.63T
Revenue per share (ttm)	142,523.30
Quarterly revenue growth (yoy)	-1.60%
Gross profit (ttm)	N/A
EBITDA	109.81B
Net income avi to common (ttm)	-26.63B
Diluted EPS (ttm)	N/A
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	55.51B
Total cash per share (mrq)	4,863.34
Total debt (mrq)	724.02B
Total debt/equity (mrq)	47.02%
Current ratio (mrq)	1.20
Book value per share (mrq)	N/A

Cash flow statement

Operating cash flow (ttm)	-5.47B
Levered free cash flow (ttm)	-166.64B